IBD immunopathogenesis: A comprehensive review of inflammatory molecules

Autoimmunity Reviews

Volumn 16, Issue 4, 2017, Pages 416-426

  Park, Jae Hyon ^a   Peyrin Biroulet, Laurent ^b   Eisenhut, Michael ^c   Shin, Jae Il ^a  

^a Yonsei University College of Medicine   (South Korea)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c BEDFORD HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; INFLAMMASOME; MACROPHAGE DERIVED CHEMOKINE; MICRORNA; NEUROPEPTIDE; ANTIINFLAMMATORY AGENT;

ANGIOGENESIS; ANTIGEN PRESENTING CELL; APOPTOSIS; CROHN DISEASE; DENDRITIC CELL; EFFECTOR CELL; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LYMPHOID CELL; MAST CELL; MOLECULAR PATHOLOGY; NATURAL KILLER T CELL; NONHUMAN; REVIEW; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INFLAMMASOMES; INFLAMMATORY BOWEL DISEASES;

EID: 85014096222     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.02.013     Document Type: Review

References (195)

1. [1] Neurath, M.F., Cytokines in inflammatory bowel disease. Nat Rev Immunol 14:5 (2014), 329–342.
2. [2] Di Sabatino, A., Lenti, M.V., Giuffrida, P., Vanoli, A., Corazza, G.R., New insights into immune mechanisms underlying autoimmune diseases of the gastrointestinal tract. Autoimmun Rev 14:12 (2015), 1161–1169.
3. [3] Cassinotti, A., Sarzi-Puttini, P., Fichera, M., Shoenfeld, Y., de Franchis, R., Ardizzone, S., Immunity, autoimmunity and inflammatory bowel disease. Autoimmun Rev 13:1 (2014), 1–2.
4. [4] Geremia, A., Biancheri, P., Allan, P., Corazza, G.R., Di Sabatino, A., Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 13:1 (2014), 3–10.
5. [5] Danese, S., Fiocchi, C., Ulcerative colitis. N Engl J Med 365:18 (2011), 1713–1725.
6. [6] Ben-Horin, S., Kopylov, U., Chowers, Y., Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 13:1 (2014), 24–30.
7. [7] Fiorino, G., Danese, S., Pariente, B., Allez, M., Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents. Autoimmun Rev 13:1 (2014), 15–19.
8. [8] Ng, S.C., Benjamin, J.L., McCarthy, N.E., Hedin, C.R., Koutsoumpas, A., Plamondon, S., et al. Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn's disease. Inflamm Bowel Dis 17:10 (2011), 2027–2037.
9. [9] Casini-Raggi, V., Kam, L., Chong, Y.J., Fiocchi, C., Pizarro, T.T., Cominelli, F., Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 154:5 (1995), 2434–2440.
10. [10] Coccia, M., Harrison, O.J., Schiering, C., Asquith, M.J., Becher, B., Powrie, F., et al. IL-1beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J Exp Med 209:9 (2012), 1595–1609.
11. [11] Cominelli, F., Nast, C.C., Clark, B.D., Schindler, R., Lierena, R., Eysselein, V.E., et al. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 86:3 (1990), 972–980.
12. [12] Pizarro, T.T., Michie, M.H., Bentz, M., Woraratanadharm, J., Smith, M.F. Jr., Foley, E., et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 162:11 (1999), 6829–6835.
13. [13] Atreya, R., Mudter, J., Finotto, S., Mullberg, J., Jostock, T., Wirtz, S., et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 6:5 (2000), 583–588.
14. [14] Yamamoto, M., Yoshizaki, K., Kishimoto, T., Ito, H., IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 164:9 (2000), 4878–4882.
15. [15] Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126:4 (2004), 989–996.
16. [16] Atreya, R., Zimmer, M., Bartsch, B., Waldner, M.J., Atreya, I., Neumann, H., et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+) macrophages. Gastroenterology 141:6 (2011), 2026–2038.
17. [17] Van den Brande, J.M., Braat, H., van den Brink, G.R., Versteeg, H.H., Bauer, C.A., Hoedemaeker, I., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124:7 (2003), 1774–1785.
18. [18] Van den Brande, J.M., Koehler, T.C., Zelinkova, Z., Bennink, R.J., te Velde, A.A., ten Cate, F.J., et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 56:4 (2007), 509–517.
19. [19] Strober, W., Fuss, I.J., Blumberg, R.S., The immunology of mucosal models of inflammation. Annu Rev Immunol 20 (2002), 495–549.
20. [20] Ben-Horin, S., Chowers, Y., Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 11:4 (2014), 243–255.
21. [21] Monteleone, G., Biancone, L., Marasco, R., Morrone, G., Marasco, O., Luzza, F., et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112:4 (1997), 1169–1178.
22. [22] Liu, Z., Yadav, P.K., Xu, X., Su, J., Chen, C., Tang, M., et al. The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity. J Leukoc Biol 89:4 (2011), 597–606.
23. [23] Ina, K., Itoh, J., Fukushima, K., Kusugami, K., Yamaguchi, T., Kyokane, K., et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 163:2 (1999), 1081–1090.
24. [24] Cox, J.H., Kljavin, N.M., Ramamoorthi, N., Diehl, L., Batten, M., Ghilardi, N., IL-27 promotes T cell-dependent colitis through multiple mechanisms. J Exp Med 208:1 (2011), 115–123.
25. [25] Visperas, A., Do, J.S., Bulek, K., Li, X., Min, B., IL-27, targeting antigen-presenting cells, promotes Th17 differentiation and colitis in mice. Mucosal Immunol 7:3 (2014), 625–633.
26. [26] Troy, A.E., Zaph, C., Du, Y., Taylor, B.C., Guild, K.J., Hunter, C.A., et al. IL-27 regulates homeostasis of the intestinal CD4 + effector T cell pool and limits intestinal inflammation in a murine model of colitis. J Immunol 183:3 (2009), 2037–2044.
27. [27] Hanson, M.L., Hixon, J.A., Li, W., Felber, B.K., Anver, M.R., Stewart, C.A., et al. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology 146:1 (2014), 210–221.
28. [28] Wirtz, S., Billmeier, U., McHedlidze, T., Blumberg, R.S., Neurath, M.F., Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology 141:5 (2011), 1875–1886.
29. [29] Katakura, K., Lee, J., Rachmilewitz, D., Li, G., Eckmann, L., Raz, E., Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest 115:3 (2005), 695–702.
30. [30] Rimoldi, M., Chieppa, M., Salucci, V., Avogadri, F., Sonzogni, A., Sampietro, G.M., et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 6:5 (2005), 507–514.
31. [31] Hart, A.L., Al-Hassi, H.O., Rigby, R.J., Bell, S.J., Emmanuel, A.V., Knight, S.C., et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 129:1 (2005), 50–65.
32. [32] Middel, P., Raddatz, D., Gunawan, B., Haller, F., Radzun, H.J., Increased number of mature dendritic cells in Crohn's disease: evidence for a chemokine mediated retention mechanism. Gut 55:2 (2006), 220–227.
33. [33] Smythies, L.E., Sellers, M., Clements, R.H., Mosteller-Barnum, M., Meng, G., Benjamin, W.H., et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 115:1 (2005), 66–75.
34. [34] Kamada, N., Hisamatsu, T., Okamoto, S., Chinen, H., Kobayashi, T., Sato, T., et al. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest 118:6 (2008), 2269–2280.
35. [35] Gelbmann, C.M., Mestermann, S., Gross, V., Kollinger, M., Scholmerich, J., Falk, W., Strictures in Crohn's disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin. Gut 45:2 (1999), 210–217.
36. [36] Andoh, A., Deguchi, Y., Inatomi, O., Yagi, Y., Bamba, S., Tsujikawa, T., et al. Immunohistochemical study of chymase-positive mast cells in inflammatory bowel disease. Oncol Rep 16:1 (2006), 103–107.
37. [37] Vivinus-Nebot, M., Frin-Mathy, G., Bzioueche, H., Dainese, R., Bernard, G., Anty, R., et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 63:5 (2014), 744–752.
38. [38] Kurashima, Y., Amiya, T., Nochi, T., Fujisawa, K., Haraguchi, T., Iba, H., et al. Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. Nat Commun, 3, 2012, 1034.
39. [39] Winterkamp, S., Weidenhiller, M., Otte, P., Stolper, J., Schwab, D., Hahn, E.G., et al. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Am J Gastroenterol 97:12 (2002), 3071–3077.
40. [40] Ligumsky, M., Kuperstein, V., Nechushtan, H., Zhang, Z., Razin, E., Analysis of cytokine profile in human colonic mucosal Fc epsilonRI-positive cells by single cell PCR: inhibition of IL-3 expression in steroid-treated IBD patients. FEBS Lett 413:3 (1997), 436–440.
41. [41] Boeckxstaens, G., Mast cells and inflammatory bowel disease. Curr Opin Pharmacol 25 (2015), 45–49.
42. [42] Leeb, S.N., Vogl, D., Gunckel, M., Kiessling, S., Falk, W., Goke, M., et al. Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase. Gastroenterology 125:5 (2003), 1341–1354.
43. [43] Gordon, I.O., Agrawal, N., Goldblum, J.R., Fiocchi, C., Rieder, F., Fibrosis in ulcerative colitis: mechanisms, features, and consequences of a neglected problem. Inflamm Bowel Dis 20:11 (2014), 2198–2206.
44. [44] Burke, J.P., Mulsow, J.J., O'Keane, C., Docherty, N.G., Watson, R.W., O'Connell, P.R., Fibrogenesis in Crohn's disease. Am J Gastroenterol 102:2 (2007), 439–448.
45. [45] Heuschkel, R.B., MacDonald, T.T., Monteleone, G., Bajaj-Elliott, M., Smith, J.A., Pender, S.L., Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut 47:1 (2000), 57–62.
46. [46] Kirkegaard, T., Hansen, A., Bruun, E., Brynskov, J., Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 53:5 (2004), 701–709.
47. [47] Pastorelli, L., Garg, R.R., Hoang, S.B., Spina, L., Mattioli, B., Scarpa, M., et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A 107:17 (2010), 8017–8022.
48. [48] Grobeta, P., Doser, K., Falk, W., Obermeier, F., Hofmann, C., IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm Bowel Dis 18:10 (2012), 1900–1909.
49. [49] Dubuquoy, L., Jansson, E.A., Deeb, S., Rakotobe, S., Karoui, M., Colombel, J.F., et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 124:5 (2003), 1265–1276.
50. [50] Imaeda, H., Takahashi, K., Fujimoto, T., Kasumi, E., Ban, H., Bamba, S., et al. Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol 172:3 (2013), 410–416.
51. [51] McNamee, E.N., Masterson, J.C., Jedlicka, P., McManus, M., Grenz, A., Collins, C.B., et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci U S A 108:40 (2011), 16711–16716.
52. [52] Xu, W.D., Zhao, Y., Liu, Y., Insights into IL-37, the role in autoimmune diseases. Autoimmun Rev 14:12 (2015), 1170–1175.
53. [53] Pickert, G., Neufert, C., Leppkes, M., Zheng, Y., Wittkopf, N., Warntjen, M., et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 206:7 (2009), 1465–1472.
54. [54] Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z.W., Egan, L.J., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:3 (2004), 285–296.
55. [55] Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.Y., Vallabhapurapu, S., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:2 (2009), 103–113.
56. [56] Popivanova, B.K., Kitamura, K., Wu, Y., Kondo, T., Kagaya, T., Kaneko, S., et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118:2 (2008), 560–570.
57. [57] Wang, Y., Wang, K., Han, G.C., Wang, R.X., Xiao, H., Hou, C.M., et al. Neutrophil infiltration favors colitis-associated tumorigenesis by activating the interleukin-1 (IL-1)/IL-6 axis. Mucosal Immunol 7:5 (2014), 1106–1115.
58. [58] Bollrath, J., Phesse, T.J., von Burstin, V.A., Putoczki, T., Bennecke, M., Bateman, T., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15:2 (2009), 91–102.
59. [59] Huber, S., Gagliani, N., Zenewicz, L.A., Huber, F.J., Bosurgi, L., Hu, B., et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491:7423 (2012), 259–263.
60. [60] Stolfi, C., Rizzo, A., Franze, E., Rotondi, A., Fantini, M.C., Sarra, M., et al. Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med 208:11 (2011), 2279–2290.
61. [61] Kirchberger, S., Royston, D.J., Boulard, O., Thornton, E., Franchini, F., Szabady, R.L., et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med 210:5 (2013), 917–931.
62. [62] Nathan, C., Epidemic inflammation: pondering obesity. Mol Med 14:7–8 (2008), 485–492.
63. [63] Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., Ferrante, A.W. Jr., Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:12 (2003), 1796–1808.
64. [64] Piccinini, A.M., Midwood, K.S., DAMPening inflammation by modulating TLR signalling. Mediators Inflamm, 2010 (672395).
65. [65] Takahashi, F., Das, K.M., Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-bound immunoglobulin G from idiopathic ulcerative colitis. J Clin Invest 76:1 (1985), 311–318.
66. [66] Das, K.M., Vecchi, M., Sakamaki, S., A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology 98:2 (1990), 464–469.
67. [67] Geng, X., Biancone, L., Dai, H.H., Lin, J.J., Yoshizaki, N., Dasgupta, A., et al. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology 114:5 (1998), 912–922.
68. [68] Duerr, R.H., Targan, S.R., Landers, C.J., LaRusso, N.F., Lindsay, K.L., Wiesner, R.H., et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 100:5 Pt 1 (1991), 1385–1391.
69. [69] Wiik, A., Neutrophil-specific autoantibodies in chronic inflammatory bowel diseases. Autoimmun Rev 1:1–2 (2002), 67–72.
70. [70] Mow, W.S., Vasiliauskas, E.A., Lin, Y.C., Fleshner, P.R., Papadakis, K.A., Taylor, K.D., et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 126:2 (2004), 414–424.
71. [71] McKenzie, H., Main, J., Pennington, C.R., Parratt, D., Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut 31:5 (1990), 536–538.
72. [72] Lodes, M.J., Cong, Y., Elson, C.O., Mohamath, R., Landers, C.J., Targan, S.R., et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 113:9 (2004), 1296–1306.
73. [73] Weigmann, B., Lehr, H.A., Yancopoulos, G., Valenzuela, D., Murphy, A., Stevens, S., et al. The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis. J Exp Med 205:9 (2008), 2099–2110.
74. [74] Xu, W.D., Pan, H.F., Ye, D.Q., Xu, Y., Targeting IRF4 in autoimmune diseases. Autoimmun Rev 11:12 (2012), 918–924.
75. [75] Fais, S., Capobianchi, M.R., Pallone, F., Di Marco, P., Boirivant, M., Dianzani, F., et al. Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon gamma inducers. Gut 32:4 (1991), 403–407.
76. [76] Breese, E., Braegger, C.P., Corrigan, C.J., Walker-Smith, J.A., MacDonald, T.T., Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology 78:1 (1993), 127–131.
77. [77] Sakuraba, A., Sato, T., Kamada, N., Kitazume, M., Sugita, A., Hibi, T., Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology 137:5 (2009), 1736–1745.
78. [78] Parrello, T., Monteleone, G., Cucchiara, S., Monteleone, I., Sebkova, L., Doldo, P., et al. Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease. J Immunol 165:12 (2000), 7234–7239.
79. [79] Neurath, M.F., Weigmann, B., Finotto, S., Glickman, J., Nieuwenhuis, E., Iijima, H., et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 195:9 (2002), 1129–1143.
80. [80] Szabo, S.J., Sullivan, B.M., Stemmann, C., Satoskar, A.R., Sleckman, B.P., Glimcher, L.H., Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 295:5553 (2002), 338–342.
81. [81] de Souza, H.S., Fiocchi, C., Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol 13:1 (2016), 13–27.
82. [82] Fuss, I.J., Neurath, M., Boirivant, M., Klein, J.S., de la Motte, C., Strong, S.A., et al. Disparate CD4 + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157:3 (1996), 1261–1270.
83. [83] Fuss, I.J., Strober, W., The role of IL-13 and NK T cells in experimental and human ulcerative colitis. Mucosal Immunol 1:Suppl. 1 (2008), S31–S33.
84. [84] Heller, F., Florian, P., Bojarski, C., Richter, J., Christ, M., Hillenbrand, B., et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129:2 (2005), 550–564.
85. [85] West, G.A., Matsuura, T., Levine, A.D., Klein, J.S., Fiocchi, C., Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity. Gastroenterology 110:6 (1996), 1683–1695.
86. [86] Slebioda, T.J., Bojarska-Junak, A., Stanislawowski, M., Cyman, M., Wierzbicki, P.M., Rolinski, J., et al. TL1A as a potential local inducer of IL17A expression in colon mucosa of inflammatory bowel disease patients. Scand J Immunol 82:4 (2015), 352–360.
87. [87] Schreiber, S., Heinig, T., Thiele, H.G., Raedler, A., Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108:5 (1995), 1434–1444.
88. [88] Autschbach, F., Braunstein, J., Helmke, B., Zuna, I., Schurmann, G., Niemir, Z.I., et al. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am J Pathol 153:1 (1998), 121–130.
89. [89] Ivanov, I.I., Atarashi, K., Manel, N., Brodie, E.L., Shima, T., Karaoz, U., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139:3 (2009), 485–498.
90. [90] Becker, C., Wirtz, S., Blessing, M., Pirhonen, J., Strand, D., Bechthold, O., et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest 112:5 (2003), 693–706.
91. [91] Kobayashi, T., Okamoto, S., Hisamatsu, T., Kamada, N., Chinen, H., Saito, R., et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57:12 (2008), 1682–1689.
92. [92] Kleinschek, M.A., Boniface, K., Sadekova, S., Grein, J., Murphy, E.E., Turner, S.P., et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med 206:3 (2009), 525–534.
93. [93] Siakavellas, S.I., Bamias, G., Role of the IL-23/IL-17 axis in Crohn's disease. Discov Med 14:77 (2012), 253–262.
94. [94] Dambacher, J., Beigel, F., Zitzmann, K., De Toni, E.N., Goke, B., Diepolder, H.M., et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut 58:9 (2009), 1207–1217.
95. [95] Monteleone, G., Monteleone, I., Fina, D., Vavassori, P., Del Vecchio, Blanco G., Caruso, R., et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 128:3 (2005), 687–694.
96. [96] Fina, D., Sarra, M., Fantini, M.C., Rizzo, A., Caruso, R., Caprioli, F., et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 134:4 (2008), 1038–1048.
97. [97] Brand, S., Beigel, F., Olszak, T., Zitzmann, K., Eichhorst, S.T., Otte, J.M., et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 290:4 (2006), G827–G838.
98. [98] Hainzl, E., Stockinger, S., Rauch, I., Heider, S., Berry, D., Lassnig, C., et al. Intestinal epithelial cell tyrosine kinase 2 transduces IL-22 signals to protect from acute colitis. J Immunol 195:10 (2015), 5011–5024.
99. [99] Annunziato, F., Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., Mazzinghi, B., et al. Phenotypic and functional features of human Th17 cells. J Exp Med 204:8 (2007), 1849–1861.
100. [100] Becker, C., Dornhoff, H., Neufert, C., Fantini, M.C., Wirtz, S., Huebner, S., et al. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol 177:5 (2006), 2760–2764.
101. [101] Gerlach, K., Hwang, Y., Nikolaev, A., Atreya, R., Dornhoff, H., Steiner, S., et al. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol 15:7 (2014), 676–686.
102. [102] Leung, J.M., Davenport, M., Wolff, M.J., Wiens, K.E., Abidi, W.M., Poles, M.A., et al. IL-22-producing CD4 + cells are depleted in actively inflamed colitis tissue. Mucosal Immunol 7:1 (2014), 124–133.
103. [103] Asseman, C., Mauze, S., Leach, M.W., Coffman, R.L., Powrie, F., An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190:7 (1999), 995–1004.
104. [104] Powrie, F., Carlino, J., Leach, M.W., Mauze, S., Coffman, R.L., A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4 + T cells. J Exp Med 183:6 (1996), 2669–2674.
105. [105] Huber, S., Gagliani, N., Esplugues, E., O'Connor, W. Jr., Huber, F.J., Chaudhry, A., et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(−) and Foxp3 + regulatory CD4 + T cells in an interleukin-10-dependent manner. Immunity 34:4 (2011), 554–565.
106. [106] Chaudhry, A., Rudra, D., Treuting, P., Samstein, R.M., Liang, Y., Kas, A., et al. CD4 + regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326:5955 (2009), 986–991.
107. [107] Monteleone, G., Kumberova, A., Croft, N.M., McKenzie, C., Steer, H.W., MacDonald, T.T., Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 108:4 (2001), 601–609.
108. [108] Fantini, M.C., Rizzo, A., Fina, D., Caruso, R., Sarra, M., Stolfi, C., et al. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology 136:4 (2009), 1308–1316.
109. [109] Huibregtse, I.L., van Lent, A.U., van Deventer, S.J., Immunopathogenesis of IBD: insufficient suppressor function in the gut?. Gut 56:4 (2007), 584–592.
110. [110] Takayama, T., Kamada, N., Chinen, H., Okamoto, S., Kitazume, M.T., Chang, J., et al. Imbalance of NKp44(+)NKp46(−) and NKp44(−)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology 139:3 (2010), 882–892.
111. [111] Pariente, B., Mocan, I., Camus, M., Dutertre, C.A., Ettersperger, J., Cattan, P., et al. Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4 + T cells of patients with Crohn's disease. Gastroenterology 141:1 (2011), 217–226.
112. [112] Fuss, I.J., Joshi, B., Yang, Z., Degheidy, H., Fichtner-Feigl, S., de Souza, H., et al. IL-13Ralpha2-bearing, type II NKT cells reactive to sulfatide self-antigen populate the mucosa of ulcerative colitis. Gut 63:11 (2014), 1728–1736.
113. [113] Goldberg, R., Prescott, N., Lord, G.M., MacDonald, T.T., Powell, N., The unusual suspects–innate lymphoid cells as novel therapeutic targets in IBD. Nat Rev Gastroenterol Hepatol 12:5 (2015), 271–283.
114. [114] Szabo, S.J., Kim, S.T., Costa, G.L., Zhang, X., Fathman, C.G., Glimcher, L.H., A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100:6 (2000), 655–669.
115. [115] Bernink, J.H., Peters, C.P., Munneke, M., te Velde, A.A., Meijer, S.L., Weijer, K., et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol 14:3 (2013), 221–229.
116. [116] Vonarbourg, C., Mortha, A., Bui, V.L., Hernandez, P.P., Kiss, E.A., Hoyler, T., et al. Regulated expression of nuclear receptor RORgammat confers distinct functional fates to NK cell receptor-expressing RORgammat(+) innate lymphocytes. Immunity 33:5 (2010), 736–751.
117. [117] Schulthess, J., Meresse, B., Ramiro-Puig, E., Montcuquet, N., Darche, S., Begue, B., et al. Interleukin-15-dependent NKp46 + innate lymphoid cells control intestinal inflammation by recruiting inflammatory monocytes. Immunity 37:1 (2012), 108–121.
118. [118] Fuchs, A., Vermi, W., Lee, J.S., Lonardi, S., Gilfillan, S., Newberry, R.D., et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells. Immunity 38:4 (2013), 769–781.
119. [119] Kim, B.S., Artis, D., Group 2 innate lymphoid cells in health and disease. Cold Spring Harb Perspect Biol, 2015, 7(5).
120. [120] Licona-Limon, P., Kim, L.K., Palm, N.W., Flavell, R.A., TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 14:6 (2013), 536–542.
121. [121] von Moltke, J., Ji, M., Liang, H.E., Locksley, R.M., Tuft-cell-derived IL-25 regulates an intestinal ILC2-epithelial response circuit. Nature 529:7585 (2016), 221–225.
122. [122] Siracusa, M.C., Saenz, S.A., Hill, D.A., Kim, B.S., Headley, M.B., Doering, T.A., et al. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. Nature 477:7363 (2011), 229–233.
123. [123] Powell, N., Walker, A.W., Stolarczyk, E., Canavan, J.B., Gokmen, M.R., Marks, E., et al. The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor + innate lymphoid cells. Immunity 37:4 (2012), 674–684.
124. [124] Bailey, J.R., Bland, P.W., Tarlton, J.F., Peters, I., Moorghen, M., Sylvester, P.A., et al. IL-13 promotes collagen accumulation in Crohn's disease fibrosis by down-regulation of fibroblast MMP synthesis: a role for innate lymphoid cells?. PLoS One, 7(12), 2012, e52332.
125. [125] Geremia, A., Arancibia-Carcamo, C.V., Fleming, M.P., Rust, N., Singh, B., Mortensen, N.J., et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 208:6 (2011), 1127–1133.
126. [126] Danese, S., Sans, M., Fiocchi, C., Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 3:5 (2004), 394–400.
127. [127] Hooper, L.V., Littman, D.R., Macpherson, A.J., Interactions between the microbiota and the immune system. Science 336:6086 (2012), 1268–1273.
128. [128] D'Haens, G.R., Geboes, K., Peeters, M., Baert, F., Penninckx, F., Rutgeerts, P., Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114:2 (1998), 262–267.
129. [129] Casellas, F., Borruel, N., Papo, M., Guarner, F., Antolin, M., Videla, S., et al. Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm Bowel Dis 4:1 (1998), 1–5.
130. [130] Macpherson, A., Khoo, U.Y., Forgacs, I., Philpott-Howard, J., Bjarnason, I., Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38:3 (1996), 365–375.
131. [131] Pirzer, U., Schonhaar, A., Fleischer, B., Hermann, E., Meyer zum Buschenfelde, K.H., Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn's disease. Lancet 338:8777 (1991), 1238–1239.
132. [132] Man, S.M., Kaakoush, N.O., Mitchell, H.M., The role of bacteria and pattern-recognition receptors in Crohn's disease. Nat Rev Gastroenterol Hepatol 8:3 (2011), 152–168.
133. [133] Manichanh, C., Borruel, N., Casellas, F., Guarner, F., The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 9:10 (2012), 599–608.
134. [134] Borruel, N., Carol, M., Casellas, F., Antolin, M., de Lara, F., Espin, E., et al. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 51:5 (2002), 659–664.
135. [135] Carol, M., Borruel, N., Antolin, M., Llopis, M., Casellas, F., Guarner, F., et al. Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn's disease. J Leukoc Biol 79:5 (2006), 917–922.
136. [136] Llopis, M., Antolin, M., Carol, M., Borruel, N., Casellas, F., Martinez, C., et al. Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa. Inflamm Bowel Dis 15:2 (2009), 275–283.
137. [137] Pender, S.L., Do metalloproteinases contribute to tissue destruction or remodeling in the inflamed gut?. Inflamm Bowel Dis 14:Suppl. 2 (2008), S136–S137.
138. [138] Chassaing, B., Darfeuille-Michaud, A., The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140:6 (2011), 1720–1728.
139. [139] Chassaing, B., Rolhion, N., de Vallee, A., Salim, S.Y., Prorok-Hamon, M., Neut, C., et al. Crohn disease–associated adherent-invasive E. coli bacteria target mouse and human Peyer's patches via long polar fimbriae. J Clin Invest 121:3 (2011), 966–975.
140. [140] Hansen, R., Russell, R.K., Reiff, C., Louis, P., McIntosh, F., Berry, S.H., et al. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis. Am J Gastroenterol 107:12 (2012), 1913–1922.
141. [141] Andoh, A., Imaeda, H., Aomatsu, T., Inatomi, O., Bamba, S., Sasaki, M., et al. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol 46:4 (2011), 479–486.
142. [142] Gevers, D., Kugathasan, S., Denson, L.A., Vazquez-Baeza, Y., Van Treuren, W., Ren, B., et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 15:3 (2014), 382–392.
143. [143] Willing, B.P., Dicksved, J., Halfvarson, J., Andersson, A.F., Lucio, M., Zheng, Z., et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 139:6 (2010), 1844–1854.
144. [144] Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermudez-Humaran, L.G., Gratadoux, J.J., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:43 (2008), 16731–16736.
145. [145] Frank, D.N., St Amand, A.L., Feldman, R.A., Boedeker, E.C., Harpaz, N., Pace, N.R., Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104:34 (2007), 13780–13785.
146. [146] Lepage, P., Hasler, R., Spehlmann, M.E., Rehman, A., Zvirbliene, A., Begun, A., et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 141:1 (2011), 227–236.
147. [147] Ohkusa, T., Sato, N., Ogihara, T., Morita, K., Ogawa, M., Okayasu, I., Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol 17:8 (2002), 849–853.
148. [148] Ohkusa, T., Okayasu, I., Ogihara, T., Morita, K., Ogawa, M., Sato, N., Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 52:1 (2003), 79–83.
149. [149] Ott, S.J., Musfeldt, M., Wenderoth, D.F., Hampe, J., Brant, O., Folsch, U.R., et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 53:5 (2004), 685–693.
150. [150] Quinton, J.F., Sendid, B., Reumaux, D., Duthilleul, P., Cortot, A., Grandbastien, B., et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 42:6 (1998), 788–791.
151. [151] Fritz, T., Niederreiter, L., Adolph, T., Blumberg, R.S., Kaser, A., Crohn's disease: NOD2, autophagy and ER stress converge. Gut 60:11 (2011), 1580–1588.
152. [152] Wehkamp, J., Harder, J., Weichenthal, M., Mueller, O., Herrlinger, K.R., Fellermann, K., et al. Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 9:4 (2003), 215–223.
153. [153] Wehkamp, J., Salzman, N.H., Porter, E., Nuding, S., Weichenthal, M., Petras, R.E., et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 102:50 (2005), 18129–18134.
154. [154] Bjarnason, I., O'Morain, C., Levi, A.J., Peters, T.J., Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology 85:2 (1983), 318–322.
155. [155] Wyatt, J., Vogelsang, H., Hubl, W., Waldhoer, T., Lochs, H., Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 341:8858 (1993), 1437–1439.
156. [156] Birchenough, G.M., Johansson, M.E., Gustafsson, J.K., Bergstrom, J.H., Hansson, G.C., New developments in goblet cell mucus secretion and function. Mucosal Immunol 8:4 (2015), 712–719.
157. [157] Buisine, M.P., Desreumaux, P., Debailleul, V., Gambiez, L., Geboes, K., Ectors, N., et al. Abnormalities in mucin gene expression in Crohn's disease. Inflamm Bowel Dis 5:1 (1999), 24–32.
158. [158] Buhner, S., Buning, C., Genschel, J., Kling, K., Herrmann, D., Dignass, A., et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation?. Gut 55:3 (2006), 342–347.
159. [159] Prager, M., Buttner, J., Haas, V., Baumgart, D.C., Sturm, A., Zeitz, M., et al. The JAK2 variant rs10758669 in Crohn's disease: altering the intestinal barrier as one mechanism of action. Int J Colorectal Dis 27:5 (2012), 565–573.
160. [160] Scaldaferri, F., Vetrano, S., Sans, M., Arena, V., Straface, G., Stigliano, E., et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 136:2 (2009), 585–595.
161. [161] Schirbel, A., Kessler, S., Rieder, F., West, G., Rebert, N., Asosingh, K., et al. Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis. Gastroenterology 144:3 (2013), 613–623.
162. [162] Gross, K.J., Pothoulakis, C., Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis 13:7 (2007), 918–932.
163. [163] Kabouridis, P.S., Pachnis, V., Emerging roles of gut microbiota and the immune system in the development of the enteric nervous system. J Clin Invest 125:3 (2015), 956–964.
164. [164] Sturm, A., Leite, A.Z., Danese, S., Krivacic, K.A., West, G.A., Mohr, S., et al. Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis. Gut 53:11 (2004), 1624–1631.
165. [165] de Souza, H.S., West, G.A., Rebert, N., de la Motte, C., Drazba, J., Fiocchi, C., Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn's disease. Gastroenterology 143:4 (2012), 1017–1026.
166. [166] Charo, I.F., Ransohoff, R.M., The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:6 (2006), 610–621.
167. [167] Johnson, Z., Schwarz, M., Power, C.A., Wells, T.N., Proudfoot, A.E., Multi-faceted strategies to combat disease by interference with the chemokine system. Trends Immunol 26:5 (2005), 268–274.
168. [168] Grimm, M.C., Doe, W.F., Chemokines in inflammatory bowel disease mucosa: expression of RANTES, macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and gamma-interferon-inducible protein-10 by macrophages, lymphocytes, endothelial cells, and granulomas. Inflamm Bowel Dis 2:2 (1996), 88–96.
169. [169] Uguccioni, M., Gionchetti, P., Robbiani, D.F., Rizzello, F., Peruzzo, S., Campieri, M., et al. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol 155:2 (1999), 331–336.
170. [170] Sans, M., Danese, S., de la Motte, C., de Souza, H.S., Rivera-Reyes, B.M., West, G.A., et al. Enhanced recruitment of CX3CR1 + T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease. Gastroenterology 132:1 (2007), 139–153.
171. [171] Mahida, Y.R., Ceska, M., Effenberger, F., Kurlak, L., Lindley, I., Hawkey, C.J., Enhanced synthesis of neutrophil-activating peptide-1/interleukin-8 in active ulcerative colitis. Clin Sci (Lond) 82:3 (1992), 273–275.
172. [172] Papadakis, K.A., Prehn, J., Moreno, S.T., Cheng, L., Kouroumalis, E.A., Deem, R., et al. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 121:2 (2001), 246–254.
173. [173] Strowig, T., Henao-Mejia, J., Elinav, E., Flavell, R., Inflammasomes in health and disease. Nature 481:7381 (2012), 278–286.
174. [174] Opipari, A., Franchi, L., Role of inflammasomes in intestinal inflammation and Crohn's disease. Inflamm Bowel Dis 21:1 (2015), 173–181.
175. [175] Simovic Markovic, B., Nikolic, A., Gazdic, M., Bojic, S., Vucicevic, L., Kosic, M., et al. Gal-3 plays an important pro-inflammatory role in the induction phase of acute colitis by promoting activation of NLRP3 inflammasome and production of IL-beta in macrophages. J Crohns Colitis 10:5 (2016), 593–606.
176. [176] Rebane, A., Akdis, C.A., MicroRNAs: essential players in the regulation of inflammation. J Allergy Clin Immunol 132:1 (2013), 15–26.
177. [177] Iborra, M., Bernuzzi, F., Invernizzi, P., Danese, S., MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. Autoimmun Rev 11:5 (2012), 305–314.
178. [178] Wu, F., Zikusoka, M., Trindade, A., Dassopoulos, T., Harris, M.L., Bayless, T.M., et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 135:5 (2008), 1624–1635.
179. [179] Pekow, J.R., Dougherty, U., Mustafi, R., Zhu, H., Kocherginsky, M., Rubin, D.T., et al. miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis 18:1 (2012), 94–100.
180. [180] Koukos, G., Polytarchou, C., Kaplan, J.L., Morley-Fletcher, A., Gras-Miralles, B., Kokkotou, E., et al. MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. Gastroenterology 145:4 (2013), 842–852.
181. [181] Rubartelli, A., Lotze, M.T., Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 28:10 (2007), 429–436.
182. [182] Foell, D., Wittkowski, H., Roth, J., Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 58:6 (2009), 859–868.
183. [183] Palone, F., Vitali, R., Cucchiara, S., Pierdomenico, M., Negroni, A., Aloi, M., et al. Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease. Inflamm Bowel Dis 20:8 (2014), 1448–1457.
184. [184] Jacob, F., Perez Novo, C., Bachert, C., Van Crombruggen, K., Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses. Purinergic Signal 9:3 (2013), 285–306.
185. [185] Scarpa, M., Bortolami, M., Cecchetto, A., Faggian, D., Kotsafti, A., Ruffolo, C., et al. Mucosal immune environment in colonic carcinogenesis: CD80 up-regulation in colonic dysplasia in ulcerative colitis. Eur J Cancer 47:4 (2011), 611–619.
186. [186] Nathan, C., Ding, A., Nonresolving inflammation. Cell 140:6 (2010), 871–882.
187. [187] Bonneau, J., Dumestre-Perard, C., Rinaudo-Gaujous, M., Genin, C., Sparrow, M., Roblin, X., et al. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes. Autoimmun Rev 14:3 (2015), 231–245.
188. [188] Laass, M.W., Roggenbuck, D., Conrad, K., Diagnosis and classification of Crohn's disease. Autoimmun Rev 13:4–5 (2014), 467–471.
189. [189] Conrad, K., Roggenbuck, D., Laass, M.W., Diagnosis and classification of ulcerative colitis. Autoimmun Rev 13:4–5 (2014), 463–466.
190. [190] Bogdanos, D.P., Rigopoulou, E.I., Smyk, D.S., Roggenbuck, D., Reinhold, D., Forbes, A., et al. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. Autoimmun Rev 11:2 (2011), 143–148.
191. [191] Olivieri, I., Cantini, F., Castiglione, F., Felice, C., Gionchetti, P., Orlando, A., et al. Italian expert panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmun Rev 13:8 (2014), 822–830.
192. [192] Conigliaro, P., Chimenti, M.S., Ascolani, M., Triggianese, P., Novelli, L., Onali, S., et al. Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients. Autoimmun Rev 15:2 (2016), 184–190.
193. [193] Atzeni, F., Defendenti, C., Ditto, M.C., Batticciotto, A., Ventura, D., Antivalle, M., et al. Rheumatic manifestations in inflammatory bowel disease. Autoimmun Rev 13:1 (2014), 20–23.
194. [194] Monteleone, G., Caruso, R., Pallone, F., Targets for new immunomodulation strategies in inflammatory bowel disease. Autoimmun Rev 13:1 (2014), 11–14.
195. [195] Fiorino, G., Girolomoni, G., Lapadula, G., Orlando, A., Danese, S., Olivieri, I., The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev 13:7 (2014), 751–755.